Participate in a Clinical Trial

Greater Twin Cities Metro

U of M – Clinical Trials (7)

(1 of 7) For those with a family history of T1D:

• TrialNet Pathway to Prevention screening is offered at no cost to eligible individuals to evaluate their personal risk of developing T1D. This unique screening can identify the early stages of T1D years before any symptoms appear.  It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it. Eligible participants are between the ages of 2.5 and 45 years and have a parent, brother/sister, or child with T1D, between the ages of 2.5 and 20 years and have an aunt/uncle, cousin, grandparent, niece/nephew, or half-brother/sister with T1D, and have NOT been diagnosed with T1D.
• Ages: 2.5-45 or 2.5-20
• Contact: Beth Pappenfus 612-624-2922 [email protected]

(2 of 7) For those in Stage 1 or Stage 2 monitored in the Pathway to Prevention (PTP) study

• Continuous Glucose Monitor Derived Glucose Dynamic Index as a Diagnostic Marker for Progression to Type 1 Diabetes (Dx-T1D) This study is being done to develop a way to use information from a continuous glucose monitor (CGM) to predict a person’s progression through the Stages of Type 1 Diabetes (T1D).
• Ages: 2 years old and up
• Contact: 612-301-7040, [email protected]

(3 of 7) For adults with T1D

• CLEAR (Closed Loop and Education for hypoglycemia Awareness Restoration): The purpose of this study is to learn how to improve hypoglycemia unawareness. This study will use different types of education and devices to see if they can help people become more aware when the blood sugar is low.
• Ages:  18-75
• Contact: 612-301-7040, [email protected]

(4 of 7) Newly Diagnosed with T1D within 180 days:

• The COUR study is a Phase 1 trial focused on safety. CNP-103, nanoparticle IV, is a groundbreaking disease-modifying approach which encapsulates 4 recombinant proteins that cover more than 95% of the antigens that drive T1D. Participants must be between 12 and 35 years old, weigh at least 50 kg, and be within 180 days of diagnosis.
• Ages: 12-35
• Contact: [email protected]

(5 of 7) Newly Diagnosed with T1D within 6 months:

• WAVE T1D is a Phase 1/2 trial evaluating a multi-drug strategy: ATG (an IV immunotherapy) followed by either adalimumab (a subcutaneous anti-inflammatory) or verapamil (an oral calcium channel blocker). The goal is to assess the safety and efficacy of the therapy combinations in preserving insulin secretion 2 years from randomization in persons with recent-onset stage 3 T1D.
• Eligible participants are ages 9 to 21 and weigh more than 30 kg.
• Ages: 9-21
• Contact: [email protected]

(6 of 7) Newly Diagnosed with T1D within 100 days:

• RESET T1D is a Phase 2 study to see if rezpegaldesleukin can help the body continue making insulin in people newly diagnosed with type 1 diabetes (TID) by stimulating regulatory T cells to restore immune balance.
• Ages 8-45 years old
• Body weight criteria different for those under vs over 18yo
• Contact: [email protected]

(7 of 7) Newly Diagnosed with T1D within 6 months:

• COVID-19 Diabetes Assessment (CODA) study goal is to gain a deeper understanding of what happens in the first one to two years after a diagnosis of diabetes. The study will examine the possible impact of COVID-19 and other factors on early diabetes.
• Ages: 11 years old and up
• Contact: https://codadiabetesstudy.org/contact?contact=minn

HealthPartners International Diabetes Center (4)

(1 of 4) Newly diagnosed T1D within a month:

• BETA-PRESERVE: A randomized, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D).
  • Purpose of study: This study is looking at how an investigational study drug, called teplizumab, might possibly help protect insulin-producing cells by affecting the immune cells that attack them. The main goal of the study is to see if teplizumab can work better than a placebo (a look alike with no medicine in it) in helping people keep their blood sugar in a healthy range or use less mealtime insulin. Teplizumab is already FDA approved for use in earlier-stage of type 1 diabetes.
  • Ages: 1-25
  • Contact: Caitlin Moening, (952) 993-9605, [email protected],

(2 of 4) For adults with T1D:

• Safety and Efficacy of Adjunct Therapies in Adults with Type 1 diabetes: Multicenter, Registry Study
  • This study aims to better understand how newer medications, such as weekly GLP 1 receptor agonists and SGLT inhibitors, are being used in adults with Type 1 Diabetes.
  • Ages: 18 years old and older
  • Have been prescribed—or plan to start—a GLP 1 or SGLT2 medication such as Ozempic, Wegovy, Trulicity, Jardiance, or Farxiga, and have used it for one week
  • Contact: Caitlin Moening, (952) 993-9605, [email protected],

(3 of 4) For ages 7+ with T1D for at least 6 months:

• Medtronic CIP351 GATEWAY
  • The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5 in people with diabetes.
  • Ages: 7-85 years old
  • Contact: Caitlin Moening, (952) 993-9605, [email protected],

(4 of 4) For ages 11+ with T1D for at least 6 months:

• Efficacy of the Omnipod® 6 System Compared with the Omnipod® 5 System in Individuals with Type 1 or Type 2 Diabetes and Suboptimal Glycemia
• This trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.
  • Ages: 14-75 years old
  • A1c > 7.5%
  • Are currently using a CGM
  • Contact: Caitlin Moening, (952) 993-9605, [email protected]

Rochester

Mayo Clinic (4)

(1 of 4) For T1D diagnosed ≥ 5 years

• Evaluate the Effect of Improving Glycemic Control on Gastric Emptying in Type 1 Diabetes Mellitus
  • The purpose of this study is to evaluate the effects of improving glycemic control, and/or reducing glycemic variability on gastric emptying, intestinal barrier function, autonomic nerve functions, and epigenetic changes in subjects with T1D
  • HbA1C > 7.5%
  • Contact: Amber Galbreath, (507)538-3883, [email protected]

(2 of 4) For adults with T1D

• PACTAID
  • The purpose of this trial is to test and refine the PACTAID smart phone application in adults with type 1 diabetes mellitus to help manage exercise while on automated insulin delivery systems with the goal of improving glycemic control during and after exercise as well as improving multiple other cardiovascular risk factors.
  • Ages: 18 to 65
  • Contact: Leidy Plaza Enriquez M.D., (507) 284 2476 [email protected]

(3 of 4) For adults with T1D for 3 years or more:

• Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
  • The purpose of this study is to understand why patients with indigestion, with or without diabetes, have gastrointestinal symptoms and, in particular, to understand where the symptoms are related to increased sensitivity to nutrients. Subsequently, look at the effects of Ondansetron on these patients’ symptoms.
  • Ages: 18-75 years old
  • Contact: Amber Galbreath, (507)538-3883, [email protected]

(4 of 4) For those with a family history of T1D:

• TrialNet Pathway to Prevention screening is offered at no cost to eligible individuals to evaluate their personal risk of developing T1D. This unique screening can identify the early stages of T1D years before any symptoms appear.  It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it. Eligible participants are between the ages of 2.5 and 45 years and have a parent, brother/sister, or child with T1D, between the ages of 2.5 and 20 years and have an aunt/uncle, cousin, grandparent, niece/nephew, or half-brother/sister with T1D, and have NOT been diagnosed with T1D.
• Ages: 2.5-45 or 2.5-20
• Contact: Kailey Oehlke, (507)284-0488, [email protected]

Western Minnesota, North Dakota and South Dakota

Sanford – Clinical Trials (4)

(1 of 14) For those with a family history of T1D:

• Pathway to Prevention: TrialNet screening is offered at no cost to eligible individuals to evaluate their personal risk of developing T1D. This unique screening can identify the early stages of T1D years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it. Eligible participants are between the ages of 2.5 and 45 years and have a parent, brother/sister, or child with T1D, between the ages of 2.5 and 20 years and have an aunt/uncle, cousin, grandparent, niece/nephew, or half-brother/sister with T1D and have NOT been diagnosed with T1D.
• Location: In home or lab test kit
• Ages: 2.5 -45 or 2.5 to 20 depending on above criteria
• Contact: Sanford Fargo Region: (701) 234-2383 or Sanford Sioux Falls Region: (605) 328-1368

(2 of 4) For children 0-5 and 9-16 that do not have T1D:

• PLEDGE: General Population Screening: Since 90% of people with T1D do not have a family history of T1D, general population screening is warranted to find children at risk for T1D. The Sanford PLEDGE Study is integrating this screening into routine pediatric care delivery at Sanford primary care clinics.

(3 of 4) Newly Diagnosed with T1D within 100 days:

• SAFEGUARD: evaluates SAB-142, an investigational immunotherapy designed to delay the progression of Stage 3 New Onset Type 1 Diabetes (T1D).
• Location: Fargo, ND
• Ages: 5 to 40
• Contact: Sanford Health regional clinical research offices

(4 of 4) Patients diagnosed with Stage 2 Type 1 Diabetes

• Registry for Stage 2 Type 1 Diabetes: An observational, long-term safety study of tzield® (teplizumab-mzwv) in patients with stage 2 type 1 diabetes.
• Contact: Sanford Fargo Region: (701) 234-2383

Circle Clinical Research (1)

(1 of) For adults with T1D for 3 years or more:

• The CATT1 study is a clinical study that is researching the safety and effectiveness of the investigational drug, cadisegliatin (also called TTP399), at helping manage low blood sugar (hypoglycemia) for T1D patients.
• Ages: ≥18 years
• Contact: Circle Clinical Research at 605-215-1159

Virtual Clinical Trials

Meet your Clinical Trials Education Volunteers:

Angie Grant – [email protected]

Debbie Evans – [email protected]